Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads your Heart's future: new test spots cancer drug danger

NCT ID NCT07515859

Knowledge-focused Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at over 31,000 cancer patients to see if an AI-enhanced electrocardiogram (ECG) could predict heart damage caused by chemotherapy. Researchers analyzed existing ECGs taken before treatment to see if the AI could identify those at risk. The goal is to develop a simple, non-invasive tool to help doctors personalize cancer therapy and prevent heart failure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple, low-cost ECG test to identify patients at high risk of heart damage before starting cancer therapy.
What could go wrong
This is a retrospective study, not a controlled trial, so results may not apply to all patients. The AI tool needs further validation in prospective studies before clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

31,486 people

The number who actually took part.

Started

May 2006

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who were prescribed anthracycline, HER2 inhibitor, or ICI agents and have ECG prescription within 90 days before their first chemotherapy treatment at Severance hospital from May 2006 to November 2022.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients prescribed anthracycline (doxorubicin, daunorubicin, epirubicin, aclarubicin, idarubicin), HER2 inhibitor (trastuzumab, emtansine, tucatinib, trastuzumab deruxtecan, pertuzumab), or immune checkpoint inhibitors (ipilimumab, nivolumab, atezolizumab, pembrolizumab, durvalumab, avelumab) * ECG performed within 90 days prior to the first chemotherapy treatment * Age ≥ 19 years * For trajectory analysis: patients with an additional ECG within 90 days after the first chemotherapy Exclusion Criteria: * Age \< 19 years * History of heart failure, cardiomyopathy, or myocarditis (confirmed by ICD codes) * Prior exposure to anthracycline, HER2 inhibitor, or immune checkpoint inhibitor therapy * Baseline left ventricular ejection fraction (LVEF) \< 40% on echocardiography within 1 year prior to chemotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer therapy-related cardiac dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cardiotoxicity heart failure left ventricular failure Ventricular Dysfunction, Left

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer therapy-related cardiac dysfunction Heart failure Left ventricular dysfunction

Contacts and locations

Locations

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.